NASDAQ:BGNE BeiGene - BGNE Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding BeiGene, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. $215.65 -10.20 (-4.52%) (As of 03/22/2023 12:00 AM ET) Add Compare Share Share Today's Range$215.65▼$222.1550-Day Range$215.59▼$274.5052-Week Range$118.18▼$280.62Volume88,981 shsAverage Volume242,225 shsMarket Capitalization$22.50 billionP/E RatioN/ADividend YieldN/APrice Target$292.86 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media BeiGene MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside35.8% Upside$292.86 Price TargetShort InterestBearish1.94% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.14Based on 4 Articles This WeekInsider TradingSelling Shares$18.47 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($12.65) to ($8.23) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.30 out of 5 starsMedical Sector234th out of 986 stocksPharmaceutical Preparations Industry98th out of 477 stocks 4.5 Analyst's Opinion Consensus RatingBeiGene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $292.86, BeiGene has a forecasted upside of 35.8% from its current price of $215.65.Amount of Analyst CoverageBeiGene has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted1.94% of the outstanding shares of BeiGene have been sold short.Short Interest Ratio / Days to CoverBeiGene has a short interest ratio ("days to cover") of 8.Change versus previous monthShort interest in BeiGene has recently increased by 4.12%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldBeiGene does not currently pay a dividend.Dividend GrowthBeiGene does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BGNE. Previous Next 2.3 News and Social Media Coverage News SentimentBeiGene has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.34 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for BeiGene this week, compared to 4 articles on an average week.Search Interest11 people have searched for BGNE on MarketBeat in the last 30 days. This is an increase of 450% compared to the previous 30 days.MarketBeat Follows2 people have added BeiGene to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BeiGene insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $18,469,758.00 in company stock.Percentage Held by InsidersOnly 7.50% of the stock of BeiGene is held by insiders.Percentage Held by Institutions51.43% of the stock of BeiGene is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for BeiGene are expected to grow in the coming year, from ($12.65) to ($8.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BeiGene is -11.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BeiGene is -11.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBeiGene has a P/B Ratio of 5.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About BeiGene (NASDAQ:BGNE) StockBeiGene Ltd. is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.Read More Receive BGNE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BeiGene and its competitors with MarketBeat's FREE daily newsletter. Email Address BGNE Stock News HeadlinesMarch 21, 2023 | finance.yahoo.comBeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New JerseyMarch 19, 2023 | americanbankingnews.comBeiGene, Ltd. (NASDAQ:BGNE) Receives $292.86 Average Target Price from AnalystsMarch 23, 2023 | Upexi, Inc (Ad)The Stock That Is Flying Under Wall St. RadarWith The Founder OF XPO Logistics Leading The Way This Nasdaq Company is Ready and GOING!March 17, 2023 | finance.yahoo.comBeiGene Will Not Go Forward With Licensing Pact For Leap Therapeutics' Lead Cancer CandidateMarch 16, 2023 | americanbankingnews.comBeiGene (NASDAQ:BGNE) Now Covered by StockNews.comFebruary 28, 2023 | finance.yahoo.comDown -15.66% in 4 Weeks, Here's Why You Should You Buy the Dip in BeiGene, Ltd. (BGNE)February 27, 2023 | finance.yahoo.comHere's Why BeiGene, Ltd. (BGNE) is Poised for a Turnaround After Losing -17.02% in 4 WeeksFebruary 27, 2023 | finance.yahoo.comBeiGene Reports Fourth Quarter and Full Year 2022 Financial ResultsMarch 23, 2023 | Upexi, Inc (Ad)The Stock That Is Flying Under Wall St. RadarWith The Founder OF XPO Logistics Leading The Way This Nasdaq Company is Ready and GOING!February 24, 2023 | finance.yahoo.comBeiGene Receives 10th Approval for PD-1 Inhibitor Tislelizumab in ChinaFebruary 24, 2023 | finance.yahoo.comBeiGene to Present at Cowen’s 43rd Annual Healthcare ConferenceFebruary 23, 2023 | finance.yahoo.comIs a Surprise Coming for BeiGene (BGNE) This Earnings Season?February 22, 2023 | finance.yahoo.comDown -14.15% in 4 Weeks, Here's Why BeiGene, Ltd. (BGNE) Looks Ripe for a TurnaroundFebruary 15, 2023 | finance.yahoo.comIs Apexigen, Inc. (APGN) Stock Outpacing Its Medical Peers This Year?February 6, 2023 | finance.yahoo.comQuebec becomes first province to cover PrBRUKINSA® (zanubrutinib) for the Treatment of Waldenström's macroglobulinemiaFebruary 3, 2023 | finance.yahoo.comIs There An Opportunity With BeiGene, Ltd.'s (NASDAQ:BGNE) 40% Undervaluation?January 20, 2023 | finance.yahoo.comFDA Approves BeiGene's Brukinsa For Chronic Lymphocytic LeukemiaJanuary 19, 2023 | finance.yahoo.comBRUKINSA® Approved in the U.S. for Chronic Lymphocytic LeukemiaJanuary 19, 2023 | finance.yahoo.comBRUKINSA® (zanubrutinib) Receives Marketing Authorization for Chronic Lymphocytic Leukemia (CLL) and Marginal Zone Lymphoma (MZL) in Great Britain by MHRAJanuary 18, 2023 | finance.yahoo.comBeiGene Announces Expansion of Coverage on China’s National Reimbursement Drug ListJanuary 17, 2023 | finance.yahoo.comBeiGene Presents New Research from Tislelizumab Global Development Program at 2023 ASCO Gastrointestinal Cancers SymposiumJanuary 16, 2023 | finance.yahoo.comWhat Makes BeiGene, Ltd. (BGNE) a Good Fit for 'Trend Investing'January 4, 2023 | finance.yahoo.comBeiGene to Present at the J.P. Morgan 41st Annual Healthcare ConferenceDecember 30, 2022 | finance.yahoo.comBeiGene Announces Acceptance of 12th Regulatory Submission in China for PD-1 Inhibitor TislelizumabDecember 13, 2022 | finance.yahoo.comBeiGene’s BRUKINSA® (zanubrutinib) Demonstrated Superior Progression-Free Survival Over IMBRUVICA® (ibrutinib) in Chronic Lymphocytic Leukemia in Late-Breaker at ASHDecember 13, 2022 | msn.comBeiGene Earnings Perspective: Return On Capital EmployedDecember 13, 2022 | markets.businessinsider.comWhat 5 Analyst Ratings Have To Say About BeiGeneSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive BGNE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BeiGene and its competitors with MarketBeat's FREE daily newsletter. Email Address BGNE Company Calendar Last Earnings2/27/2023Today3/23/2023Next Earnings (Estimated)5/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BGNE CUSIPN/A CIK1651308 Webwww.beigene.com Phone(345) 949-4123FaxN/AEmployees9,200Year Founded2010Price Target and Rating Average Stock Price Forecast$292.86 High Stock Price Forecast$350.00 Low Stock Price Forecast$213.00 Forecasted Upside/Downside+35.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($19.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-2,003,810,000.00 Net Margins-141.86% Pretax Margin-138.50% Return on Equity-39.72% Return on Assets-28.19% Debt Debt-to-Equity Ratio0.05 Current Ratio3.55 Quick Ratio3.35 Sales & Book Value Annual Sales$1.42 billion Price / Sales15.89 Cash FlowN/A Price / Cash FlowN/A Book Value$42.17 per share Price / Book5.11Miscellaneous Outstanding Shares104,320,000Free Float96,491,000Market Cap$22.50 billion OptionableOptionable Beta0.77 Social Links Key ExecutivesJohn V. OylerChairman & Chief Executive OfficerXiao Bin WuPresident & Chief Operating OfficerJulia WangChief Financial & Accounting OfficerChristiane LangerSenior Vice President-Global Medical AffairsMark LanasaChief Medical OfficerKey CompetitorsAlnylam PharmaceuticalsNASDAQ:ALNYGenmab A/SNASDAQ:GMABHorizon Therapeutics PublicNASDAQ:HZNPBioMarin PharmaceuticalNASDAQ:BMRNCatalentNYSE:CTLTView All CompetitorsInsiders & InstitutionsXiaodong WangSold 67,635 sharesTotal: $15.29 M ($226.03/share)OLD Mission Capital LLCBought 26,222 shares on 3/6/2023Ownership: 0.025%Macquarie Group Ltd.Bought 542 shares on 2/21/2023Ownership: 0.023%Truist Financial CorpBought 1,136 shares on 2/17/2023Ownership: 0.001%United Capital Financial Advisers LLCSold 265 shares on 2/16/2023Ownership: 0.002%View All Insider TransactionsView All Institutional Transactions BGNE Stock - Frequently Asked Questions Should I buy or sell BeiGene stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BeiGene in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BGNE shares. View BGNE analyst ratings or view top-rated stocks. What is BeiGene's stock price forecast for 2023? 6 brokerages have issued 1 year price objectives for BeiGene's shares. Their BGNE share price forecasts range from $213.00 to $350.00. On average, they expect the company's share price to reach $292.86 in the next twelve months. This suggests a possible upside of 35.8% from the stock's current price. View analysts price targets for BGNE or view top-rated stocks among Wall Street analysts. How have BGNE shares performed in 2023? BeiGene's stock was trading at $219.94 at the beginning of 2023. Since then, BGNE shares have decreased by 2.0% and is now trading at $215.65. View the best growth stocks for 2023 here. When is BeiGene's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. View our BGNE earnings forecast. How were BeiGene's earnings last quarter? BeiGene, Ltd. (NASDAQ:BGNE) released its quarterly earnings data on Monday, February, 27th. The company reported ($4.29) EPS for the quarter, missing analysts' consensus estimates of ($4.18) by $0.11. The company had revenue of $380.10 million for the quarter, compared to analyst estimates of $388.17 million. BeiGene had a negative net margin of 141.86% and a negative trailing twelve-month return on equity of 39.72%. The company's revenue for the quarter was up 77.6% on a year-over-year basis. During the same period in the prior year, the company posted ($6.22) EPS. What ETFs hold BeiGene's stock? ETFs with the largest weight of BeiGene (NASDAQ:BGNE) stock in their portfolio include Direxion mRNA ETF (MSGR), VanEck Biotech ETF (BBH), Loncar Cancer Immunotherapy ETF (CNCR), Loncar China BioPharma ETF (CHNA), Virtus LifeSci Biotech Products ETF (BBP), Global X Aging Population ETF (AGNG), iShares Biotechnology ETF (IBB) and Invesco Nasdaq Biotechnology ETF (IBBQ). What is John V. Oyler's approval rating as BeiGene's CEO? 58 employees have rated BeiGene Chief Executive Officer John V. Oyler on Glassdoor.com. John V. Oyler has an approval rating of 69% among the company's employees. 42.0% of employees surveyed would recommend working at BeiGene to a friend. What other stocks do shareholders of BeiGene own? Based on aggregate information from My MarketBeat watchlists, some companies that other BeiGene investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), Block (SQ), Intuitive Surgical (ISRG), JD.com (JD), Intel (INTC), Baidu (BIDU), Marvell Technology (MRVL) and Cisco Systems (CSCO). When did BeiGene IPO? (BGNE) raised $126 million in an initial public offering on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at a price of $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company acted as the underwriters for the IPO and Baird was co-manager. What is BeiGene's stock symbol? BeiGene trades on the NASDAQ under the ticker symbol "BGNE." Who are BeiGene's major shareholders? BeiGene's stock is owned by many different retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (3.27%), Price T Rowe Associates Inc. MD (0.44%), Bank of America Corp DE (0.30%), Geode Capital Management LLC (0.24%), Fairmount Funds Management LLC (0.23%) and Morgan Stanley (0.17%). Insiders that own company stock include Amgen Inc, Bros Advisors Lp Baker, Donald W Glazer, Howard Liang, Jane Huang, John Oyler, Julia Aijun Wang, Lai Wang, Ltd Beigene, Timothy Yung-Cheng Chen, Xiaobin Wu and Xiaodong Wang. View institutional ownership trends. How do I buy shares of BeiGene? Shares of BGNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is BeiGene's stock price today? One share of BGNE stock can currently be purchased for approximately $215.65. How much money does BeiGene make? BeiGene (NASDAQ:BGNE) has a market capitalization of $22.50 billion and generates $1.42 billion in revenue each year. The company earns $-2,003,810,000.00 in net income (profit) each year or ($19.48) on an earnings per share basis. How many employees does BeiGene have? The company employs 9,200 workers across the globe. How can I contact BeiGene? BeiGene's mailing address is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. The official website for the company is www.beigene.com. The company can be reached via phone at (345) 949-4123 or via email at ir@beigene.com. This page (NASDAQ:BGNE) was last updated on 3/23/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.